The laboratory developed tests market sits where clinical need, scientific innovation, and regulation meet. Laboratory-developed tests (LDTs) are diagnostic tests designed, manufactured, and performed within a single clinical laboratory, which allows a lab to respond when no commercial assay meets a clinical requirement. According to Polaris Market Research, the market was valued at USD 14.16 billion in 2025 and is projected to reach USD 26.97 billion by 2034, registering a 7.4% CAGR from 2026 to 2034. For laboratory directors, diagnostic suppliers, and investors, the forces behind that trajectory deserve close attention.

How LDTs Differ from Commercial Diagnostic Tests

LDTs are created for the laboratory that performs them, whereas commercial diagnostic tests are developed by manufacturers and marketed to many healthcare facilities. A laboratory sets the performance of its own test and can modify the method as needs change, while commercial tests usually require manufacturer approval for modifications. That flexibility explains why LDTs serve specialized and emerging medical purposes, such as biomarkers that routine kits do not cover.

The typical workflow runs from identifying a clinical need through development, validation, sampling, testing, and interpretation, ending with delivery of results to the healthcare provider to support diagnosis, treatment selection, or patient monitoring.

Regulatory Clarity in 2026

Regulation remains one of the most closely watched issues for LDT developers. In May 2024, the FDA issued a final rule that brought LDTs more clearly within its medical device regulations and planned to phase out general enforcement discretion. Laboratory and pathology groups challenged it, and on March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the rule in American Clinical Laboratory Association v. FDA. The FDA chose not to appeal and later removed the 2024 regulatory changes.

The FDA LDT rule vacated outcome matters because the additional requirements planned under that framework no longer form the basis of LDT oversight, so laboratories do not have to prepare for the phased FDA requirements that would have followed. Clinical laboratories remain subject to CLIA regulation, administered by CMS, which sets standards for laboratory personnel, test methods, quality control, and reporting. Other federal requirements and state rules can also apply, and future policy changes could still influence the market. For developers, the change removes a significant source of anticipated compliance costs.

Molecular Diagnostics Anchors Technology Demand

By technology, molecular diagnostics led the market with a 26.1% share in 2025. Laboratories rely on molecular methods to detect infectious agents and genetic mutations and to analyze biomarkers linked to cancers and inherited diseases. The growing number of molecular targets lets laboratories tailor tests to specific clinical needs and adapt them as new biomarkers emerge.

Approaches such as next-generation sequencing and digital PCR are also becoming more common, helping identify genetic mutations that traditional techniques cannot evaluate. Immunoassays, meanwhile, are projected to grow at an 8.1% CAGR as interest in biomarker-based testing opens avenues for specialized assays.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/laboratory-developed-tests-market 

Companion Diagnostics and Precision Oncology

The shift toward biomarker-driven therapies is expanding opportunities for companion diagnostics. Drug manufacturers increasingly develop therapies for small population groups for whom existing tests are unsuitable, and LDTs let laboratories design assays around new biomarkers. In April 2025, Quest Diagnostics launched AD-Detect Abeta 42/40 and p-tau217 Evaluation, a laboratory-developed test that combines blood biomarkers to identify patients who may be candidates for early Alzheimer's antibody treatment. In September 2026, Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer.

Oncology shows why precision oncology matters to this market. The oncology segment led applications with a 22.8% share in 2025, because cancer diagnosis can require testing for genetic and molecular markers that commercial tests do not cover. In June 2026, Myriad Genetics announced improved accessibility of its Precise MRD test for breast, colorectal, and renal cancers, and Mayo Clinic Laboratories highlighted a Genome-Wide Methylation Array that helps classify difficult CNS tumors. Such examples reflect a broader movement toward increasingly specific cancer tests.

Regional Performance

North America led in 2025 with a 37.8% share, supported by rising healthcare expenditure, government support, and strong demand for molecular tests in cancer and genetic diseases. Europe accounted for a 29.6% share. Asia Pacific is projected to grow at an 8.6% CAGR as healthcare services expand and laboratory infrastructure investment increases in China, Japan, India, and South Korea. Latin America is projected to grow at a 6.9% CAGR and the Middle East & Africa at 6.4%.

Key Players

The competitive landscape is fragmented, with large diagnostics networks competing against specialized laboratories. Established reference and hospital-network laboratories include Labcorp, Quest Diagnostics Incorporated, Mayo Clinic Laboratories, ARUP Laboratories, Inc., and NeoGenomics Laboratories, Inc. Diagnostic technology providers include Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Siemens Healthineers AG, while Illumina, Inc., QIAGEN N.V., Guardant Health, Inc., and 23andMe focus on genetic and molecular testing. Quanterix Corporation concentrates on highly sensitive biomarker measurement.

Conclusion

The laboratory developed tests market is being shaped by specialization, molecular innovation, and a clearer U.S. regulatory position. Laboratories that pair strong assay development with sound CLIA-based quality systems are best placed to meet demand in oncology, genetic disease, and rare conditions. While reimbursement and practice differences remain challenges, the market is expected to keep developing around clinical needs for specialized testing.

More Trending Latest Reports By Polaris Market Research:

Spring Market

Electric Two Wheeler Market

AI Video Generator Market

C-Beauty Products Market

Lithium-Ion Battery Market

Cleanroom Technology Market

Aircraft Fuel Systems Market

Small Modular Reactor Market

Flow Chemistry Market